Jennifer Gershman, Pharm.D., CPh


Medication Safety Considerations for COVID-19 Treatment Paxlovid

January 11, 2022

Smaller doses are recommended for people with moderate renal impairment and the treatment should not be taken by people with serious kidney disease. There are also drug interactions to be aware of because Paxlovid is an inhibitor of CYP3A.